OpenGate Capital Announces Acquisition of Majority Interest in InRule Technology, Inc.
19.8.2019 15:00:00 EEST | Business Wire | Press release
OpenGate Capital, a global private equity firm, announced today that it has acquired InRule Technology, Inc. (“InRule”), a market-leading decision management platform and business rules management system (BRMS). OpenGate is pleased to partner with the co-founders of InRule to continue innovation and leadership in the decision management market. This transaction marks the fifth investment completed in 2019 through OpenGate Capital’s second institutional fund. Financial terms were not disclosed.
InRule software powers mission-critical decisions for enterprise and government customers. InRule provides an end-to-end, fully auditable platform that acts as a “single source of truth” for enterprises processing complex business rules and decision workflows. Its decision platform drives significant and quantifiable business value across a variety of use cases, including insurance eligibility, mortgage qualification, risk rating and fraud reduction, regulatory compliance, healthcare claims processing and CPQ calculations. InRule has diverse, global and long-standing relationships with more than 400 customers across a variety of industries, including financial services, public sector, IT and business services, healthcare and insurance. Headquartered in Chicago, Illinois and founded in 2002, InRule will continue to be led by Co-Founder and CEO Rik Chomko; Co-Founder and CTO Loren Goodman; and a team of industry veterans.
“We are pleased to partner with OpenGate, a global private equity firm that shares our goal to be the global leader in the decision management market,” said Rik Chomko, InRule Co-Founder and CEO. "InRule remains deeply committed to the markets we serve, and we now have greater flexibility to invest in our customers, technology, people and future. I am proud of our employees, and all that we have accomplished together; we are transforming the way complex decisions are managed by the enterprise. InRule has never been better positioned for success.”
Andrew Nikou, OpenGate Capital’s founder and CEO, commented, “InRule is an exciting investment for OpenGate when we consider the vital nature of decision automation in today’s increasingly complex world. InRule’s unique ability to process complex logic and vast amounts of data is critical at a time when governance, compliance and digital transformation are vital to any organization’s success. OpenGate’s investment in InRule is a tremendous point of pride and we welcome the business into our portfolio.”
OpenGate Capital sourced InRule through its global origination team led by Joshua Adams, Managing Director – Business Development; and Rafael Baron, Vice President – Business Development. From the firm’s Los Angeles office, the following team members are responsible for negotiating and overseeing the investment: Robert Young, Principal – M&A; and Paul Bridwell, Managing Director – Operations.
The acquisition of InRule follows the recently completed acquisitions of Duraco from Essentra, Sargent and Greenleaf from Stanley Black & Decker, SMAC from Colas Group, and Fiven from Saint-Gobain.
About OpenGate Capital
Founded in 2005, OpenGate Capital is a global private equity firm that strives to acquire and optimize lower middle market businesses throughout North America and Europe with a strategic focus on operational improvement, innovation and growth. OpenGate is headquartered in Los Angeles and Paris and has a seasoned in-house team of professionals overseeing the entire lifecycle of each investment. To learn more about OpenGate, please visit www.opengatecapital.com.
About InRule Technology, Inc.
InRule Technology® enables enterprises to understand and automate decisions with unparalleled speed, agility, accuracy and transparency. IT and business personnel rely on InRule’s Decision Platform and Business Rules Management System (BRMS) to increase productivity, grow revenue and enhance customer service. With its ‘author first’ approach, InRule empowers both technical and business rule authors to write and manage rules. From on-premises, to the cloud and via mobile, InRule allows organizations to run rules anywhere for extreme flexibility and scalability. More than 400 InRule User Community members depend on InRule to reduce development and change cycles by 90 percent for their mission critical systems and customer-facing applications. InRule has been delivering measurable business and IT results in high-performance environments since 2002. For more information visit www.inrule.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005134/en/
Contact information
OpenGate Media Contacts
Alanna Chaffin
Email: achaffin@opengatecapital.com
Telephone: +1 (310) 432-7000
Mike Sitrick
Sitrick & Company
Email: Mike_Sitrick@sitrick.com
Telephone: (310) 788-2850
OpenGate Business Development Contacts
Joshua Adams
Email: jadams@opengatecapital.com
Telephone: +1 (310) 432-7000
Rafael Baron
Email: rbaron@opengatecapital.com
Telephone: +1 (310) 432-7000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom